APA (7th ed.) Citation

A, O., M, T., T, F., K, M., K, M., M, H., . . . A, M. (2025). Comparative effectiveness of subcutaneous sarilumab 200 mg biweekly, subcutaneous Tocilizumab 162 mg biweekly, and intravenous Tocilizumab 8 mg/kg every 4 weeks in patients with rheumatoid arthritis: A prospective cohort study. Arthritis research & therapy, 27(1), 52. https://doi.org/10.1186/s13075-025-03514-x

Chicago Style (17th ed.) Citation

A, Onishi, et al. "Comparative Effectiveness of Subcutaneous Sarilumab 200 mg Biweekly, Subcutaneous Tocilizumab 162 mg Biweekly, and Intravenous Tocilizumab 8 mg/kg Every 4 Weeks in Patients with Rheumatoid Arthritis: A Prospective Cohort Study." Arthritis Research & Therapy 27, no. 1 (2025): 52. https://doi.org/10.1186/s13075-025-03514-x.

MLA (9th ed.) Citation

A, Onishi, et al. "Comparative Effectiveness of Subcutaneous Sarilumab 200 mg Biweekly, Subcutaneous Tocilizumab 162 mg Biweekly, and Intravenous Tocilizumab 8 mg/kg Every 4 Weeks in Patients with Rheumatoid Arthritis: A Prospective Cohort Study." Arthritis Research & Therapy, vol. 27, no. 1, 2025, p. 52, https://doi.org/10.1186/s13075-025-03514-x.